Dementia with Lewy Bodies (DLB) is the second most frequent cause of age related neurodegenerative dementia, accounting for approximately a third of all dementias. The presence of Lewy bodies in the brain is linked to low levels of important chemical messengers and the loss of connection between nerve cells. This leads to the progressive death of nerve cells and loss of brain tissue.

This report provides the current prevalent population for Lewy Body Dementia across 12 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of Lewy Body Dementia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Lewy Body Dementia disease include:

• Problems with alertness and attention, which fluctuate over the course of a day
• Day-to-day memory problems
• Visual hallucinations
• Problems with motor control
• Somatoform disorders
• Issues organizing
• Rapid eye movement sleep disorders
• Problems with distance perception

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Lewy Body Dementia market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Lewy Body Dementia and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Lewy Body Dementia prevalent population.
• Identify sub-populations within Lewy Body Dementia which require treatment.
• Gain an understanding of the specific markets that have the largest number of Lewy Body Dementia patients.